Clinical Trials Browser

Phase 1 × HuMax-IL8 × Clear all

NCT04572451 2025-08-01

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Phase 1 Recruiting

Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site

NCT02536469 2017-02-03

HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumor